Literature DB >> 16319366

Use of nicotine replacement therapy and the risk of acute myocardial infarction, stroke, and death.

R Hubbard1, S Lewis, C Smith, C Godfrey, L Smeeth, P Farrington, J Britton.   

Abstract

OBJECTIVE: To determine whether nicotine replacement therapy (NRT) is associated with an increased risk of acute myocardial infarction, acute stroke, or death.
DESIGN: Self control case series analysis of data from The Health Improvement Network (THIN) to estimate the relative incidence of myocardial infarction and stroke in four 14 day periods before and after the first prescription for NRT.
SETTING: THIN is a computerised general practice database.
SUBJECTS: Patients contributing data to THIN.
INTERVENTIONS: Observational study of NRT. MAIN OUTCOMES: Acute myocardial infarction, acute stroke, and death.
RESULTS: 33,247 individuals had been prescribed NRT, of whom 861 had had a myocardial infarction and 506 a stroke. There was a progressive increase in the incidence of first myocardial infarction in the 56 days leading up to the first NRT prescription (overall incidence ratio 5.55, 95% confidence interval (CI) 4.42 to 6.98), but the incidence fell after this time and was not increased in the 56 days after starting NRT (incidence ratio 1.27, 95% CI 0.82 to 1.97). The results were similar for second myocardial infarction and stroke, and for subgroups of people with pre-existing angina and hypertension. There were 960 deaths in our cohort during a mean follow up period of 2.6 years after starting NRT, with no evidence of an increased mortality in the 56 days after the NRT prescription (incidence ratio 0.86, 95% CI 0.60 to 1.23).
CONCLUSIONS: The use of NRT is not associated with any increase in the risk of myocardial infarction, stroke, or death.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16319366      PMCID: PMC1748112          DOI: 10.1136/tc.2005.011387

Source DB:  PubMed          Journal:  Tob Control        ISSN: 0964-4563            Impact factor:   7.552


  22 in total

1.  WHO Europe evidence based recommendations on the treatment of tobacco dependence.

Authors:  M Raw; P Anderson; A Batra; G Dubois; P Harrington; A Hirsch; J Le Houezec; A McNeill; D Milner; M Poetschke Langer; W Zatonski
Journal:  Tob Control       Date:  2002-03       Impact factor: 7.552

Review 2.  Case series analysis of adverse reactions to vaccines: a comparative evaluation.

Authors:  C P Farrington; J Nash; E Miller
Journal:  Am J Epidemiol       Date:  1996-06-01       Impact factor: 4.897

3.  Real-world efficacy of prescription and over-the-counter nicotine replacement therapy.

Authors:  Saul Shiffman; Clyde N Rolf; Stephen J Hellebusch; Jane Gorsline; Charles W Gorodetzky; Yu-Kun Chiang; Debra S Schleusener; Michael E Di Marino
Journal:  Addiction       Date:  2002-05       Impact factor: 6.526

4.  Five-hundred life-saving interventions and their cost-effectiveness.

Authors:  T O Tengs; M E Adams; J S Pliskin; D G Safran; J E Siegel; M C Weinstein; J D Graham
Journal:  Risk Anal       Date:  1995-06       Impact factor: 4.000

5.  Reducing antibiotic use for acute bronchitis in primary care: blinded, randomised controlled trial of patient information leaflet.

Authors:  John Macfarlane; William Holmes; Philip Gard; David Thornhill; Rosamund Macfarlane; Richard Hubbard
Journal:  BMJ       Date:  2002-01-12

6.  Smoking cessation guidelines for health professionals: an update. Health Education Authority.

Authors:  R West; A McNeill; M Raw
Journal:  Thorax       Date:  2000-12       Impact factor: 9.139

Review 7.  Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment.

Authors:  R J Panos; R L Mortenson; S A Niccoli; T E King
Journal:  Am J Med       Date:  1990-04       Impact factor: 4.965

8.  A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines.

Authors:  P Farrington; S Pugh; A Colville; A Flower; J Nash; P Morgan-Capner; M Rush; E Miller
Journal:  Lancet       Date:  1995-03-04       Impact factor: 79.321

9.  A naturalistic cohort study on effectiveness, safety and usage pattern of an over-the-counter nicotine patch. Cohort study on smoking cessation.

Authors:  Joerg Hasford; Karl Olov Fagerstrom; Knut-Olav Haustein
Journal:  Eur J Clin Pharmacol       Date:  2003-07-25       Impact factor: 2.953

10.  Myocardial infarction and nicotine patch: a contributing or causative factor?

Authors:  A Dacosta; J M Guy; B Tardy; R Gonthier; L Denis; M Lamaud; A Cerisier; H Verneyre
Journal:  Eur Heart J       Date:  1993-12       Impact factor: 29.983

View more
  31 in total

1.  Effect of treatment guidelines on the initial management of idiopathic pulmonary fibrosis.

Authors:  Jeffrey C Munson; Maryl Kreider; Zhen Chen; Jason D Christie; Stephen E Kimmel
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

Review 2.  [Modern medical support for smoking cessation].

Authors:  T Hering
Journal:  Internist (Berl)       Date:  2009-01       Impact factor: 0.743

3.  Estimating the risks and benefits of nicotine replacement therapy for smoking cessation in the United States.

Authors:  Benjamin J Apelberg; Georgiana Onicescu; Erika Avila-Tang; Jonathan M Samet
Journal:  Am J Public Health       Date:  2009-12-17       Impact factor: 9.308

4.  Risk of hospitalization for hip fracture and pneumonia associated with antipsychotic prescribing in the elderly: a self-controlled case-series analysis in an Australian health care claims database.

Authors:  Nicole Pratt; Elizabeth E Roughead; Emmae Ramsay; Amy Salter; Philip Ryan
Journal:  Drug Saf       Date:  2011-07-01       Impact factor: 5.606

Review 5.  Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review.

Authors:  Konstantinos E Farsalinos; Riccardo Polosa
Journal:  Ther Adv Drug Saf       Date:  2014-04

Review 6.  [Pharmacotherapeutic treatment strategies for smoking cessation].

Authors:  N Vasic; R C Wolf; N Wolf; B J Connemann; Z Sosic-Vasic
Journal:  Nervenarzt       Date:  2011-11       Impact factor: 1.214

Review 7.  The role of smoking cessation in the prevention of coronary artery disease.

Authors:  Andrew L Pipe; Sophia Papadakis; Robert D Reid
Journal:  Curr Atheroscler Rep       Date:  2010-03       Impact factor: 5.113

8.  Safety of nicotine replacement therapy in critically ill smokers: a retrospective cohort study.

Authors:  Michael A Gillies; C A McKenzie; C Whiteley; R J Beale; S M Tibby
Journal:  Intensive Care Med       Date:  2012-05-23       Impact factor: 17.440

9.  Cigarette smoke-induced left ventricular remodelling is associated with activation of mitogen-activated protein kinases.

Authors:  Lianzhi Gu; Vikas Pandey; David L Geenen; Shamim A K Chowdhury; Mariann R Piano
Journal:  Eur J Heart Fail       Date:  2008-09-24       Impact factor: 15.534

10.  Downregulation of miR-133 via MAPK/ERK signaling pathway involved in nicotine-induced cardiomyocyte apoptosis.

Authors:  Lu Wang; Xuelian Li; Yuhong Zhou; Hui Shi; Chaoqian Xu; Hua He; Shuxuan Wang; Xuehui Xiong; Yong Zhang; Zhimin Du; Ruixue Zhang; Yanjie Lu; Baofeng Yang; Hongli Shan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-11-05       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.